CGON

Business Context and Reporting Period

Company: CG Oncology, Inc. (CGON)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, a potential bladder-sparing therapy for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). The company has no approved products and generates revenue solely from license and collaboration agreements.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: License and collaboration revenue dropped to $0 for the three months ended June 30, 2025, compared to $111,000 in the prior year period. For the six months, revenue was $52,000 versus $640,000 in the prior year.
• Increased Operating Expenses: Total operating expenses rose significantly to $48.7 million for the quarter (up from $26.0 million) and $91.0 million for the six months (up from $49.0 million).
  • R&D Expenses: Increased by $12.9 million (quarter) and $23.1 million (six months), driven by higher external clinical trial costs due to patient enrollment and increased personnel costs.
  • G&A Expenses: Increased by $9.9 million (quarter) and $18.9 million (six months), primarily due to higher compensation costs (including stock-based compensation) and professional fees.
• Net Loss Expansion: Net loss widened to $41.4 million for the quarter (from $18.9 million) and $75.9 million for the six months (from $35.8 million).
• Liquidity Position: Cash and cash equivalents decreased from $257.1 million at year-end 2024 to $14.6 million at June 30, 2025, while marketable securities increased to $646.4 million. Total liquid assets remain robust at approximately $661 million.

Outlook, Risks, and Unusual Items

• Capital Runway: Management estimates existing cash, cash equivalents, and marketable securities are sufficient to fund operations into the first half of 2028.
• Regulatory Timeline: The company expects to initiate a Biologics License Application (BLA) submission to the FDA in the fourth quarter of 2025 based on the BOND-003 Cohort C Phase 3 trial.
• Legal Proceedings (ANI): In July 2025, a jury unanimously rejected all claims by ANI Pharmaceuticals regarding unjust enrichment and royalties. The company will not owe a 5% royalty on future commercial sales of cretostimogene to ANI, though ANI may appeal.
• Subsequent Event (SPV Consolidation): On July 20, 2025, the company obtained control of SP Healthcare SPV I, LLC (SPV) following a conversion event. The SPV will be consolidated into the company's financial statements effective July 20, 2025.
• At-the-Market Offering: The company entered into a sales agreement in March 2025 to sell up to $250 million of common stock; no sales have been made as of June 30, 2025.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $57.2 million operating cash burn over six months against the $661 million liquid asset base.
• BLA Submission Timing: Monitor the fourth-quarter 2025 timeline for the BLA submission and any potential delays in the BOND-003 trial data readouts.
• Legal Appeals: Track any post-trial motions or appeals filed by ANI Pharmaceuticals following the July 2025 verdict.
• SPV Consolidation Impact: Review the preliminary purchase price allocation and financial impact of consolidating the SPV in the next reporting period.
• Collaboration Revenue: Assess the likelihood of recognizing future milestone payments from Lepu Biotech and Kissei Pharmaceutical given the current lack of revenue recognition.